NCT01121653 is a Phase 4 clinical trial of Magnogene ® (magnesium) in Patient With Neuropathic Pain, sponsored by University Hospital, Clermont-Ferrand.

Who is sponsoring NCT01121653?

NCT01121653 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT01121653?

Interventions in NCT01121653: Magnogene ® (magnesium).

What condition does NCT01121653 study?

NCT01121653 studies Patient With Neuropathic Pain.

Is NCT01121653 still recruiting?

NCT01121653 is currently completed. Last updated 10 May 2010.

Last reviewed 2010-05-10 · How we verify

NCT01121653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Oral Magnesium on Neuropathic Pain

Completed Phase 4 Last updated 10 May 2010

What this trial tests

Phase 4 trial testing Magnogene ® (magnesium) in Patient With Neuropathic Pain in 50 participants. Completed in 1 June 2008.

Timeline

1 March 2006

Primary endpoint
1 January 2008

1 June 2008

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	1 March 2006
Primary completion	1 January 2008
Estimated completion	1 June 2008
Sites	1 location across France

Drugs / interventions tested

Magnogene ® (magnesium) — full drug profile →

Conditions studied

Patient With Neuropathic Pain — all drugs for Patient With Neuropathic Pain →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Patient With Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pain scores (neuropathic pain evaluation questionnaire)
Time frame: Visit D0

Sponsor's own description

Use lay language. The aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01121653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 10 May 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01121653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing